38 years after founding the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) on April 8, 1986, Rick Doblin, Ph.D., will explore nearly four decades of psychedelic triumphs and challenges. In December 2023, Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). Rick will discuss MAPS’ path toward mass mental health by means of public education, drug policy reform, and global humanitarian projects.